std-hiv-aids-2017-scientifictracks-abstracts

16 / 18

Page 34
Notes:
|
International Journal of HIV and AIDS research
International Conference on
&
Sexually Transmitted Diseases, AIDS and Parasitic Infections
Parasitology, Infectious Diseases, STDs and STIs
September 21-22, 2017 San Antonio, TX, USA
Hepatoprotective effects of vinpocetine and isosorbide-5-mononitrate in experimental
Schistosoma mansoni infection
El-Beshbishi, Samar MAlhusseiny, Maha MAbu Hashim, Hosam El-dein E El-nemr and Aya E Handoussa
Mansoura University, Egypt
Schistosoma mansoni chronically infects million people globally, causing liver fibrosis. Praziquantel (PZQ) is
the drug of choice for all human schistosome, yet the drug cannot prevent the advancement of liver fibrosis.
So, there is a pressing necessity to develop substitutes/and or adjuvants targeting the scarring process, aiming to
prevent the progression to fatal fibrosis. Our study aimed to investigate the hepatoprotective efficacy of the anti-
inflammatory drug; vinpocetine, and the vasodilator agent; isosorbide-5-mononitrate (IS-5-MN) in Schistosoma
mansoni-infected mice using some parasitological and histopathological parameters. PZQ-treated mice revealed
significant reductions in hepatic egg load and granuloma count, with non-significant reduction in granuloma
diameter and expressed the highest scores of hepatic inflammation and necrosis. While either vinpocetine or IS-5-
MN significantly reduced granuloma count and diameter. Moreover, IS-5-MN monotherapy significantly reduced
hepatic inflammation and necrosis. The best significant reductions in hydroxyproline and collagen contents
were obtained in the mice groups treated with IS-5-MN combined with PZQ or vinpocetine. In conclusion, our
results point to vinpocetine and IS-5-MN as a convenient and promising adjuvant agents to PZQ to ameliorate
schistosomal liver pathology. Future studies are recommended to reveal the efficacy of vinpocetine, IS-5-MN and
PZQ co-administration in schistosomiasis advanced liver fibrosis.
Biography
El-Beshbishi has completed her PhD-research and Post-doctoral studies from University of Texas Medical Branch, Galveston, Texas-USA. She is Professor of
Medical Parasitology, Faculty of Medicine, and Mansoura University, Egypt. She has her expertise in schistosomal therapeutic and immunological studies. She
has published more than 30 papers in reputed journals and has been serving as an Editorial Board Member and reviewer of repute.